Skip to main content
Top
Published in: Clinical Rheumatology 11/2019

01-11-2019 | Mood Disorders | Original Article

Increased risks of psychiatric disorders in patients with primary Sjögren’s syndrome—a secondary cohort analysis of nationwide, population-based health claim data

Authors: Min-Chih Hsieh, Chia-Wen Hsu, Ming-Chi Lu, Malcolm Koo

Published in: Clinical Rheumatology | Issue 11/2019

Login to get access

Abstract

Introduction/objectives

Primary Sjögren’s syndrome (pSS) is a chronic systemic autoimmune disease. The aim of this study was to investigate the risk of five common psychiatrist-diagnosed disorders in patients with pSS.

Method

Using Taiwan’s National Health Insurance Research Database, 688 patients with newly diagnosed pSS between 2000 and 2012 were identified. Two comparison cohorts were assembled, namely, 3440 patients without pSS and 1302 newly diagnosed patients with rheumatoid arthritis. The incidences of depressive disorder, anxiety disorder, bipolar disorder, sleep disorder, and schizophrenia between the pSS cohort and the comparison cohorts were compared using Poisson regression models.

Results

Patients with pSS exhibited a significantly higher risk of developing depressive disorder (adjusted incidence rate ratio [aIRR] = 2.11, p < 0.001), anxiety disorder (aIRR = 2.20, p < 0.001), and sleep disorder (aIRR = 1.76, p = 0.012) when compared with the non-pSS cohort. The risks of developing depressive, anxiety, and sleep disorders were also significantly increased when compared to the rheumatoid arthritis comparison cohort. When the analyses were stratified by sex, depressive disorder (aIRR = 2.10, p < 0.001), anxiety disorder (aIRR = 2.02, p = 0.001), and sleep disorder (aIRR = 1.74, p = 0.022) were found to be significantly increased in female patients with pSS. However, only anxiety disorder (aIRR = 4.88, p = 0.044) was also significantly increased in male patients with pSS. The peak age group of developing depressive disorder was 65–80 years old (aIRR = 3.46, p < 0.001).

Conclusions

In this retrospective cohort study based on population-based claim data, significantly increased incidences of depressive disorder, anxiety disorder, and sleep disorder were observed in patients with pSS.
Key Points
• Patients, particularly women, with primary Sjögren’s syndrome exhibited a significantly higher risk of developing depressive disorder, anxiety disorder, and sleep disorder.
• The peak age group of developing depressive disorder was 65–80 years old.
Literature
2.
3.
go back to reference Weng MY, Huang YT, Liu MF, Lu TH (2011) Incidence and mortality of treated primary Sjögren's syndrome in Taiwan: a population-based study. J Rheumatol 38(4):706–708CrossRef Weng MY, Huang YT, Liu MF, Lu TH (2011) Incidence and mortality of treated primary Sjögren's syndrome in Taiwan: a population-based study. J Rheumatol 38(4):706–708CrossRef
4.
go back to reference Kang JH, Lin HC (2010) Comorbidities in patients with primary Sjögren’s syndrome: a registry-based case-control study. J Rheumatol 37(6):1188–1194CrossRef Kang JH, Lin HC (2010) Comorbidities in patients with primary Sjögren’s syndrome: a registry-based case-control study. J Rheumatol 37(6):1188–1194CrossRef
5.
go back to reference Cui Y, Li L, Yin R, Zhao Q, Chen S, Zhang Q, Shen B (2018) Depression in primary Sjögren’s syndrome: a systematic review and meta-analysis. Psychol Health Med 23(2):198–209CrossRef Cui Y, Li L, Yin R, Zhao Q, Chen S, Zhang Q, Shen B (2018) Depression in primary Sjögren’s syndrome: a systematic review and meta-analysis. Psychol Health Med 23(2):198–209CrossRef
6.
go back to reference Wan KH, Chen LJ, Young AL (2016) Depression and anxiety in dry eye disease: a systematic review and meta-analysis. Eye (Lond) 30(12):1558–1567CrossRef Wan KH, Chen LJ, Young AL (2016) Depression and anxiety in dry eye disease: a systematic review and meta-analysis. Eye (Lond) 30(12):1558–1567CrossRef
7.
go back to reference Tishler M, Barak Y, Paran D, Yaron M (1997) Sleep disturbances, fibromyalgia and primary Sjögren’s syndrome. Clin Exp Rheumatol 15(1):71–74PubMed Tishler M, Barak Y, Paran D, Yaron M (1997) Sleep disturbances, fibromyalgia and primary Sjögren’s syndrome. Clin Exp Rheumatol 15(1):71–74PubMed
8.
go back to reference Wang LY, Chiang JH, Chen SF, Shen YC (2018) Systemic autoimmune diseases are associated with an increased risk of bipolar disorder: a nationwide population-based cohort study. J Affect Disord 227:31–37CrossRef Wang LY, Chiang JH, Chen SF, Shen YC (2018) Systemic autoimmune diseases are associated with an increased risk of bipolar disorder: a nationwide population-based cohort study. J Affect Disord 227:31–37CrossRef
9.
go back to reference Lin CE (2016) One patient with Sjögren’s syndrome presenting schizophrenia-like symptoms. Neuropsychiatr Dis Treat 12:661–663CrossRef Lin CE (2016) One patient with Sjögren’s syndrome presenting schizophrenia-like symptoms. Neuropsychiatr Dis Treat 12:661–663CrossRef
10.
go back to reference Eaton WW, Byrne M, Ewald H, Mors O, Chen CY, Agerbo E, Mortensen PB (2006) Association of schizophrenia and autoimmune diseases: linkage of Danish national registers. Am J Psychiatry 163(3):521–528CrossRef Eaton WW, Byrne M, Ewald H, Mors O, Chen CY, Agerbo E, Mortensen PB (2006) Association of schizophrenia and autoimmune diseases: linkage of Danish national registers. Am J Psychiatry 163(3):521–528CrossRef
11.
go back to reference Shen CC, Yang AC, Kuo BI, Tsai SJ (2015) Risk of psychiatric disorders following primary Sjögren syndrome: a nationwide population-based retrospective cohort study. J Rheumatol 42(7):1203–1208CrossRef Shen CC, Yang AC, Kuo BI, Tsai SJ (2015) Risk of psychiatric disorders following primary Sjögren syndrome: a nationwide population-based retrospective cohort study. J Rheumatol 42(7):1203–1208CrossRef
13.
go back to reference Vitali C, Bombardieri S, Moutsopoulos HM, Balestrieri G, Bencivelli W, Bernstein RM, Bjerrum KB, Braga S, Coll J, de Vita S et al (1993) Preliminary classification criteria for Sjögren’s syndrome. Results of a prospective concerted action supported by the European community. Arthritis Rheum 36(3):340–347CrossRef Vitali C, Bombardieri S, Moutsopoulos HM, Balestrieri G, Bencivelli W, Bernstein RM, Bjerrum KB, Braga S, Coll J, de Vita S et al (1993) Preliminary classification criteria for Sjögren’s syndrome. Results of a prospective concerted action supported by the European community. Arthritis Rheum 36(3):340–347CrossRef
14.
go back to reference Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, Daniels TE, Fox PC, Fox RI, Kassan SS, Pillemer SR, Talal N, Weisman MH, European Study Group on Classification Criteria for Sjögren’s Syndrome (2002) Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 61(6):554–558CrossRef Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, Daniels TE, Fox PC, Fox RI, Kassan SS, Pillemer SR, Talal N, Weisman MH, European Study Group on Classification Criteria for Sjögren’s Syndrome (2002) Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 61(6):554–558CrossRef
15.
go back to reference Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31(3):315–324CrossRef Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31(3):315–324CrossRef
16.
go back to reference Shen CC, Hu LY, Yang AC, Kuo BI, Chiang YY, Tsai SJ (2016) Risk of psychiatric disorders following ankylosing spondylitis: a nationwide population-based retrospective cohort study. J Rheumatol 43(3):625–631CrossRef Shen CC, Hu LY, Yang AC, Kuo BI, Chiang YY, Tsai SJ (2016) Risk of psychiatric disorders following ankylosing spondylitis: a nationwide population-based retrospective cohort study. J Rheumatol 43(3):625–631CrossRef
17.
go back to reference Lass P, Krajka-Lauer J, Homziuk M, Iwaszkiewicz-Bilikiewicz B, Koseda M, Hebanowski M, Lyczak P (2000) Cerebral blood flow in Sjögren’s syndrome using 99Tcm-HMPAO brain SPET. Nucl Med Commun 21(1):31–35CrossRef Lass P, Krajka-Lauer J, Homziuk M, Iwaszkiewicz-Bilikiewicz B, Koseda M, Hebanowski M, Lyczak P (2000) Cerebral blood flow in Sjögren’s syndrome using 99Tcm-HMPAO brain SPET. Nucl Med Commun 21(1):31–35CrossRef
18.
go back to reference Pertovaara M, Silvennoinen O, Isomäki P (2016) Cytokine-induced STAT1 activation is increased in patients with primary Sjögren’s syndrome. Clin Immunol 165:60–67CrossRef Pertovaara M, Silvennoinen O, Isomäki P (2016) Cytokine-induced STAT1 activation is increased in patients with primary Sjögren’s syndrome. Clin Immunol 165:60–67CrossRef
19.
go back to reference Grygiel-Górniak B, Limphaibool N, Puszczewicz M (2019) Cytokine secretion and the risk of depression development in patients with connective tissue diseases. Psychiatry Clin Neurosci 73(6):302–316CrossRef Grygiel-Górniak B, Limphaibool N, Puszczewicz M (2019) Cytokine secretion and the risk of depression development in patients with connective tissue diseases. Psychiatry Clin Neurosci 73(6):302–316CrossRef
20.
go back to reference Hou R, Garner M, Holmes C, Osmond C, Teeling J, Lau L, Baldwin DS (2017) Peripheral inflammatory cytokines and immune balance in generalised anxiety disorder: case-controlled study. Brain Behav Immun 62:212–218CrossRef Hou R, Garner M, Holmes C, Osmond C, Teeling J, Lau L, Baldwin DS (2017) Peripheral inflammatory cytokines and immune balance in generalised anxiety disorder: case-controlled study. Brain Behav Immun 62:212–218CrossRef
21.
go back to reference de Oliveira FR, Fantucci MZ, Adriano L, Valim V, Cunha TM, Louzada-Junior P, Rocha EM (2018) Neurological and inflammatory manifestations in Sjögren’s syndrome: the role of the kynurenine metabolic pathway. Int J Mol Sci 19(12):3953CrossRef de Oliveira FR, Fantucci MZ, Adriano L, Valim V, Cunha TM, Louzada-Junior P, Rocha EM (2018) Neurological and inflammatory manifestations in Sjögren’s syndrome: the role of the kynurenine metabolic pathway. Int J Mol Sci 19(12):3953CrossRef
22.
go back to reference Hackett KL, Gotts ZM, Ellis J, Deary V, Rapley T, Ng WF, Newton JL, Deane KH (2016) An investigation into the prevalence of sleep disturbances in primary Sjögren’s syndrome: a systematic review of the literature. Rheumatology (Oxford) 56(4):570–580 Hackett KL, Gotts ZM, Ellis J, Deary V, Rapley T, Ng WF, Newton JL, Deane KH (2016) An investigation into the prevalence of sleep disturbances in primary Sjögren’s syndrome: a systematic review of the literature. Rheumatology (Oxford) 56(4):570–580
23.
go back to reference Milin M, Cornec D, Chastaing M, Griner V, Berrouiguet S, Nowak E, Marhadour T, Saraux A, Devauchelle-Pensec V (2016) Sicca symptoms are associated with similar fatigue, anxiety, depression, and quality-of-life impairments in patients with and without primary Sjogren’s syndrome. Joint Bone Spine 83(6):681–685CrossRef Milin M, Cornec D, Chastaing M, Griner V, Berrouiguet S, Nowak E, Marhadour T, Saraux A, Devauchelle-Pensec V (2016) Sicca symptoms are associated with similar fatigue, anxiety, depression, and quality-of-life impairments in patients with and without primary Sjogren’s syndrome. Joint Bone Spine 83(6):681–685CrossRef
24.
go back to reference Kuehner C (2017) Why is depression more common among women than among men? Lancet Psychiatry 4(2):146–158CrossRef Kuehner C (2017) Why is depression more common among women than among men? Lancet Psychiatry 4(2):146–158CrossRef
25.
go back to reference Li SH, Graham BM (2017) Why are women so vulnerable to anxiety, trauma-related and stress-related disorders? The potential role of sex hormones. Lancet Psychiatry 4(1):73–82CrossRef Li SH, Graham BM (2017) Why are women so vulnerable to anxiety, trauma-related and stress-related disorders? The potential role of sex hormones. Lancet Psychiatry 4(1):73–82CrossRef
26.
go back to reference Michael T, Zetsche U, Margraf J (2007) Epidemiology of anxiety disorders. Psychiatry 6(4):136–142CrossRef Michael T, Zetsche U, Margraf J (2007) Epidemiology of anxiety disorders. Psychiatry 6(4):136–142CrossRef
27.
go back to reference Kessler RC, Bromet EJ (2013) The epidemiology of depression across cultures. Annu Rev Public Health 34:119–138CrossRef Kessler RC, Bromet EJ (2013) The epidemiology of depression across cultures. Annu Rev Public Health 34:119–138CrossRef
28.
go back to reference Seror R Ravaud P, Bowman SJ, Baron G, Tzioufas A, Theander E, Gottenberg JE, Bootsma H, Mariette X, Vitali C, EULAR Sjögren’s Task Force (2010) EULAR Sjogren’s syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren’s syndrome. Ann Rheum Dis 69(6):1103–1109CrossRef Seror R Ravaud P, Bowman SJ, Baron G, Tzioufas A, Theander E, Gottenberg JE, Bootsma H, Mariette X, Vitali C, EULAR Sjögren’s Task Force (2010) EULAR Sjogren’s syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren’s syndrome. Ann Rheum Dis 69(6):1103–1109CrossRef
29.
go back to reference Seror R, Ravaud P, Mariette X, Bootsma H, Theander E, Hansen A, Ramos-Casals M, Dörner T, Bombardieri S, Hachulla E et al (2011) EULAR Sjogren’s syndrome patient reported index (ESSPRI): development of a consensus patient index for primary Sjogren’s syndrome. Ann Rheum Dis 70(6):968–972CrossRef Seror R, Ravaud P, Mariette X, Bootsma H, Theander E, Hansen A, Ramos-Casals M, Dörner T, Bombardieri S, Hachulla E et al (2011) EULAR Sjogren’s syndrome patient reported index (ESSPRI): development of a consensus patient index for primary Sjogren’s syndrome. Ann Rheum Dis 70(6):968–972CrossRef
Metadata
Title
Increased risks of psychiatric disorders in patients with primary Sjögren’s syndrome—a secondary cohort analysis of nationwide, population-based health claim data
Authors
Min-Chih Hsieh
Chia-Wen Hsu
Ming-Chi Lu
Malcolm Koo
Publication date
01-11-2019
Publisher
Springer London
Published in
Clinical Rheumatology / Issue 11/2019
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-019-04705-z

Other articles of this Issue 11/2019

Clinical Rheumatology 11/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.